SEC Form 4 · accession 0001831215-26-000002
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kinney Horn
Officer — CHIEF BUSINESS OFFICER
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 5:38 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2026 | M | 1,092 | $12.92 | A | 1,092 | D | |
| Common Stock | Jul 7, 2026 | S | 1,092 | $25.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $12.92 | Jul 7, 2026 | M | 1,092 | D | — | Aug 8, 2034 | Common Stock | 1,092 | 128,908 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
- F225% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.